Literature DB >> 12898083

The role of pharmacotherapy in assisting smoking cessation.

W Stephen Waring1.   

Abstract

Tobacco use represents the single most important preventable health hazard world-wide. Its consumption confers substantially increased mortality and morbidity due to cardiovascular, cerebrovascular and respiratory disease, and malignancy in a number of sites. A key goal towards improving public health in developing and developed countries alike is to reduce tobacco use across populations. Despite this, current data suggest that global tobacco use is increasing. There have been recent pharmacological advances that offer the hope of achieving more effective tobacco cessation and reduced consumption among established tobacco users. These are discussed in further detail, with reference to evidence supporting their use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898083     DOI: 10.1007/s00228-003-0632-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

1.  Bupropion: a new treatment for smokers. Nicotine replacement treatment should also be available on the NHS.

Authors:  J Britton; M J Jarvis
Journal:  BMJ       Date:  2000-07-08

2.  Smoking cessation among self-quitters.

Authors:  J R Hughes; S B Gulliver; J W Fenwick; W A Valliere; K Cruser; S Pepper; P Shea; L J Solomon; B S Flynn
Journal:  Health Psychol       Date:  1992       Impact factor: 4.267

Review 3.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

Authors:  N F Woolacott; L Jones; C A Forbes; L C Mather; A J Sowden; F J Song; J P Raftery; P N Aveyard; C J Hyde; P M Barton
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

4.  DSM-III-R tobacco dependence and quitting during late adolescence.

Authors:  W R Stanton
Journal:  Addict Behav       Date:  1995 Sep-Oct       Impact factor: 3.913

Review 5.  An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke.

Authors:  C J Smith; S D Livingston; D J Doolittle
Journal:  Food Chem Toxicol       Date:  1997 Oct-Nov       Impact factor: 6.023

6.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

7.  Detection of reversible platelet aggregates in the blood of smokers and ex-smokers with peripheral vascular disease.

Authors:  V L Chiang; W M Castleden; M F Leahy
Journal:  Med J Aust       Date:  1992-05-04       Impact factor: 7.738

8.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

Authors:  N R Anthonisen; J E Connett; J P Kiley; M D Altose; W C Bailey; A S Buist; W A Conway; P L Enright; R E Kanner; P O'Hara
Journal:  JAMA       Date:  1994-11-16       Impact factor: 56.272

9.  The risk of myocardial infarction after quitting smoking in men under 55 years of age.

Authors:  L Rosenberg; D W Kaufman; S P Helmrich; S Shapiro
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

10.  Myocardial infarction and nicotine patch: a contributing or causative factor?

Authors:  A Dacosta; J M Guy; B Tardy; R Gonthier; L Denis; M Lamaud; A Cerisier; H Verneyre
Journal:  Eur Heart J       Date:  1993-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.